Company dossier
Alkem Laboratories
NSE:ALKEM · ISIN INE540L01014
- Close
- ₹5,672.5 29 Jul 2026
- Daily change
- N/A Exchange close
- Evidence state
- Building 0/0 checks
Alkem Laboratories
Financials
Structured filings
Exchange XBRLReported financial periods
| Metric | Quarter · FY26 · 31 Mar 26 | FY26 · 31 Dec 25 | Half year · FY26 · 30 Sept 25 | Quarter · FY26 · 30 Jun 25 | FY25 · 31 Mar 25 | Quarter · 31 Dec 24 |
|---|---|---|---|---|---|---|
| Revenue | ₹3,603.3 Cr | ₹3,736.8 Cr | ₹4,001 Cr | N/A | N/A | ₹3,374.3 Cr |
| Profit before tax | ₹422.9 Cr | ₹781.2 Cr | ₹895.8 Cr | N/A | N/A | ₹731.1 Cr |
| Profit after tax | ₹251.1 Cr | ₹653 Cr | ₹779.1 Cr | N/A | N/A | ₹640.8 Cr |
| Finance cost | ₹53.9 Cr | ₹42.1 Cr | ₹35 Cr | N/A | N/A | ₹36 Cr |
| Impairment | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS | ₹19.77 | ₹53.19 | ₹63.99 | N/A | N/A | ₹52.34 |
Accounting lens
Research frameworkWhat deserves analyst attention
Confirm quarterly, year-to-date and annual periods before calculating growth. The table preserves the exchange period labels.
Treat scope changes as breaks in comparability and open the linked XBRL before relying on a trend.
Sector metrics and accounting choices require additional facts beyond this common cross-company layer.